Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience Authors: Benjamin Heyman, Michael Choi, Thomas J. Kipps Published: 2026 ABSTRACT ABSTRACTIntroductionThe optimal venetoclax‐based treatment for patients with relapsed/refractory (R/R) CLL is still unknown, especially for high‐risk patients.MethodsWe performed a retrospective analysis of 98 patients with R/R CLL treated with venetoclax‐based regimens. Patients received venetoclax alone or in combination with rituximab (VenR), obinutuzumab (VenO), or a BTKi (primarily ibrutinib).ResultsCombination groups achieved higher complete remission (CR) and uMRD rates: VenO (CR 68%, uMRD 86%), VenR (CR 63%, uMRD 82%), Ven + BTKi (CR 43%, uMRD 70%), versus monotherapy (CR 51%, uMRD 67%). At a median 52‐month follow‐up, median PFS was superior in combination arms (76.6 months) compared to monotherapy (58.9 months, p = 0.04).ConclusionThis analysis validates, in a real‐world academic cohort, that venetoclax‐based combination therapy, particularly with obinutuzumab or BTKi, yields higher rates of deep remission and superior PFS compared to monotherapy for R/R CLL. Targeted therapies have transformed outcomes in chronic lymphocytic leukemia (CLL), with venetoclax‐based regimens offering deep responses and durable remissions in relapsed/refractory (R/R) settings [1, 2]. However, optimal regimen choices—particularly among combinations with anti‐CD20 antibodies or BTK inhibitors—remain a subject of ongoing investigation, especially for heavily pre‐treated and high‐risk patients [3, 4]. This study aims to clarify real‐world outcomes with venetoclax monotherapy and commonly used combinations in a diverse institutional cohort, emphasizing MRD response and clinical durability. Ninety‐eight patients with R/R CLL treated at UC San Diego between 2012 and 2024 with venetoclax‐based regimens were retrospectively included. Patients received venetoclax alone or in combination with rituximab (VenR), obinutuzumab (VenO), or a BTKi (primarily ibrutinib). Venetoclax was administered using a 5‐week ramp‐up to 400 mg daily; combination agents were dosed per established protocols. Patients who received continuous venetoclax beyond 24 months were excluded from “end of treatment” MRD analyses. MRD was quantified in peripheral blood by flow cytometry (sensitivity 10− 4), at EOT and 12 months post‐EOT. Responses were evaluated by iwCLL criteria [5]. Progression‐free survival (PFS) was calculated from therapy initiation using the Kaplan–Meier method; subgroup comparisons used the log‐rank test [6]. Multivariable Cox models assessed the impact of cytogenetic risk and MRD status. Cases with missing key data points were excluded from relevant analyses. Institutional review board approval was obtained (HRPP#171884). The median patient age was 68 (range, 46–89); most had advanced Rai stage, with a median of four prior therapies (range, 1–14) and 63% previously exposed to BTKi. High‐risk features included del(17p)/TP53 mutation in 24.7% and complex karyotype in 33%. (Table 1) TABLE 1Patient disposition.Overall N = 98 (%)Venetoclax‐based treatmentVenetoclax monotherapy43 (43.9)Venetoclax + rituximab19 (19.4)Venetoclax + obinutuzumab25 (25.5)Venetoclax + BTKi11 (11.2)Median number of months of venetoclax‐based treatment16.3 (0.9–118.6)Best responseCR63 (67)PR23 (24.5)SD1 (1.1)PD7 (7.4)Best MRD responseuMRD63 (76.8)Low MRD16 (19.5)High MRD3 (3.6)Best MRD response based on treatment Ven mono uMRD22 (66.7)Low MRD9 (27.3)High MRD2 (6.1) Ven + rituximab uMRD14 (82.4)Low MRD3 (17.6)High MRD0 Ven + obinutuzumab uMRD19 (86.4)Low MRD2 (9.1)High MRD1 (4.5) Ven + BTKi uMRD6 (60)Low MRD4 (40)High MRD0MRD response after 1 year of completion of venetoclaxuMRD25 (58.1)Low MRD13 (30.3)High MRD5 (11.6)Progression after venetoclaxNo59 (60.8)Yes38 (39.2)Subsequent treatment after venetoclaxNo61 (62.2)Yes37 (37.8)John Wiley & Sons, Ltd. Patient disposition. Treatment breakdown: venetoclax monotherapy (43.9%), VenR (19.4%), VenO (25.5%), and venetoclax + BTKi (11.2%). The median venetoclax duration was 16.3 months. At analysis, 14.3% were receiving ongoing therapy. Progression occurred in 39.2%, and 15.3% developed Richter's transformation. (Table 1) Combination groups achieved higher complete remission (CR) and uMRD rates: VenO (CR 68%, uMRD 86%), VenR (CR 63%, uMRD 82%), Ven + BTKi (CR 43%, uMRD 70%), versus monotherapy (CR 51%, uMRD 67%). At a median 52‐month follow‐up, median PFS was superior in combination arms (76.6 months) compared to monotherapy (58.9 months, p = 0.04). Presence of del(17p)/TP53 mutation and detectable MRD at 12 months post‐EOT were each associated with significantly inferior PFS (median 39.7 vs. 118 months, and 42.8 months vs. not reached, respectively). (Figure 1) Survival. (A) Kaplan–Meier estimates of progression‐free survival comparing patients treated with venetoclax monotherapy versus venetoclax‐based combination therapy. (B) Kaplan–Meier progression‐free survival curves stratified by presence or absence of del(17p)/TP53 mutation. (C) Kaplan–Meier progression‐free survival according to minimal residual disease (MRD) status in peripheral blood 12 months after completion of venetoclax‐based therapy. (D) Summary table of survival outcomes, including hazard ratios for relevant clinical and molecular risk factors. This analysis validates, in a real‐world academic cohort, that venetoclax‐based combination therapy, particularly with obinutuzumab or BTKi, yields higher rates of deep remission and superior PFS compared to monotherapy for R/R CLL [7, 8, 9, 10]. Our population was notably high‐risk, with broad prior therapy exposure and a substantial proportion carrying adverse genetic features. The strong association between sustained uMRD and prolonged remission supports MRD as a valuable prognostic tool in practice. Despite small subgroup sizes and retrospective design, our results align with established trial findings, confirming that high‐risk biology and lack of uMRD at end‐of‐treatment predict shorter remissions [11, 12]. These findings underscore the importance of individualized regimen selection and vigilant MRD monitoring post‐venetoclax. Finally, the observed effectiveness of shorter‐duration venetoclax plus obinutuzumab with lower toxicity risk has direct clinical application. Prospective studies are warranted to refine optimal strategies by disease risk and prior therapy. Limitations include single‐institution and retrospective design, modest subgroup size—especially for venetoclax + BTKi—and possible selection bias. Outcome generalizability may be affected by real‐world patient heterogeneity. Venetoclax‐based combinations, particularly with obinutuzumab or BTKi, provide superior depth and duration of response compared to monotherapy in R/R CLL in a real‐world population. MRD assessment should guide risk‐adapted monitoring and management. Author Contributions Benjamin Heyman, Michael Choi, and Thomas J. Kipps conceived the idea for the work, performed the research, and wrote the manuscript. Funding The authors have nothing to report. Ethics Statement The study was approved by the Institutional Review Board of UC San Diego (HRPP# 171884). Conflicts of Interest Benjamin Heyman received research funding and/or has served as an advisor for Astrazeneca, Beigene, Oncternal Therapeutics, Regeneron, SOBI, Guardant Health, and Incyte. Michael Choi has received research funding and/or has served as an advisor for AbbVie, AstraZeneca, Geron, Janssen, Protagonist, Beigene, and Oncternal. Thomas J. Kipps has received research funding and/or has served as an advisor to Ascerta/AstraZeneca, Celgene, Genentech/Roche, Gilead, Janssen, Loxo Oncology, Oncternal Therapeutics, Pharmacyclics/AbbVie, TG Therapeutics, VelosBio, and Verastem.